Obinutuzumab - Biologic Drug Details

Summary for obinutuzumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for obinutuzumab

Recent Clinical Trials for obinutuzumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE2
Mario Negri Institute for Pharmacological Research	PHASE2
Li Zhiming	PHASE2

See all obinutuzumab clinical trials

Pharmacology for obinutuzumab

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for obinutuzumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for obinutuzumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,035,848	2035-01-08	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,092,569	2035-02-20	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,159,675	2036-12-01	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,220,072	2037-12-06	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	6,602,684	2019-04-20	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	8,883,980	2027-08-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for obinutuzumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,035,848	2035-01-08	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,092,569	2035-02-20	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,159,675	2036-12-01	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,220,072	2037-12-06	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,227,328	2036-02-02	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,251,906	2034-03-11	Patent claims search

International Patents for obinutuzumab

Country	Patent Number	Estimated Expiration
South Korea	20180088401
Montenegro	02332
Israel	247215
European Patent Office	2380911
Slovenia	1692182
Spain	2550311

Supplementary Protection Certificates for obinutuzumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2016 00003	Denmark		PRODUCT NAME: OBINUTUZUMAB; REG. NO/DATE: EU/1/14/937 20140724
265 5003-2016	Slovakia		PRODUCT NAME: OBINUTUZUMAB; REGISTRATION NO/DATE: EU/1/14/937 20140724
300711	Netherlands		PRODUCT NAME: OBINUTUZUMAB EN ALLE VARIANTEN DAARVAN; REGISTRATION NO/DATE: EU/1/14/937 20140723
C300711	Netherlands		PRODUCT NAME: OBINUTUZUMAB EN ALLE VARIANTEN; REGISTRATION NO/DATE: EU/1/14/937 20140723
122016000021	Germany		PRODUCT NAME: OBINUTUZUMAB; REGISTRATION NO/DATE: EU/1/14/937 20140723
132015902322611	Italy		PRODUCT NAME: OBINUTUZUMAB E TUTTE LE VARIANTI DELLO STESSO(GAZYVARO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/937, 20140723

Market Dynamics and Financial Trajectory for Obinutuzumab

Last updated: February 20, 2026

Obinutuzumab (Gazyva/Gazyvaro) is a monoclonal antibody targeting CD20, approved for indications including chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). Since its 2013 global launch, its market trajectory has been shaped by competitive dynamics, regulatory developments, and evolving treatment standards.

Market Fundamentals and Indications

Obinutuzumab competes primarily with rituximab and newer agents such as obinutuzumab's other competitors, including plain rituximab biosimilars, and emerging targeted therapies. Key approved indications include:

• CLL, in combination with chlorambucil
• First-line follicular lymphoma (FL), with chemotherapy

The drug’s approval was based on trials such as the CLL11 study, demonstrating superior progression-free survival over rituximab in combination with chlorambucil. In FL, the GALLIUM trial showed improved progression-free survival compared to rituximab-based therapy.[1]

Market Size and Revenue Trends

Global sales peaked at approximately $1.1 billion in 2019, driven mainly by the U.S. and European markets. Growth plateaued as biosimilars and alternative therapies entered the market.

Year	Estimated Global Revenue (USD billion)	Notes
2015	0.2	Launch phase
2017	0.7	Uptake in CLL and FL indications
2019	1.1	Market EC expansion, exclusivity ending for some territories
2022	0.95	Market stabilization, biosimilar entry

Sales are influenced by patent expirations, market penetration, and clinical adoption rates.

Patent and Regulatory Landscape

Gazyva’s primary patent protections extended to the late 2020s, with biosimilars launching in key markets such as the U.S. and Europe starting from 2023. The introduction of biosimilars reduces the brand’s market share and pricing power.

Regulatory actions include ongoing approvals or renewals for additional indications. For instance, the FDA approved obinutuzumab for first-line FL in 2018, boosting sales.

Competitive Environment

The primary competitors are:

• Rituximab biosimilars (e.g., Truxima, Ruxience, and others)
• Obinutuzumab's rivals in targeted therapy (e.g., BTK inhibitors like ibrutinib)
• CAR T-cell therapies (for relapsed/refractory cases)

Biosimilar entry in 2023 led to significant price erosion, with discounts ranging from 30-50% compared to originator prices.

Financial Trajectory and Future Outlook

Projected revenues decline as biosimilars gain market share. Analysts forecast:

Year	Expected Revenue (USD billion)	Assumptions
2023	0.75	Biosimilar competition, patent cliffs
2025	0.65	Market consolidation, pricing pressures
2030	0.4	Dominance of biosimilars, alternative therapies

Potential revenue recovery could come from expanded indications or combination therapies. Regulatory approval for additional indications, such as marginally different lymphoma subtypes, could stabilize or slightly boost sales.

Key Factors Impacting Market Dynamics

• Biosimilar introductions in the U.S. and EU
• Physician and patient adoption rates of biosimilars
• Competitive pricing strategies and payor policies
• The emergence of novel targeted agents and CAR T-cell therapies
• Regulatory approvals for new indications or formulations

Research and Development Outlook

Biopharmaceutical companies are exploring next-generation anti-CD20 agents and combination protocols. Obinutuzumab’s pipeline includes trials for earlier-stage lymphoma, autoimmune diseases, and potential use in combination with small molecules, which could influence its future market share.

Summary

Obinutuzumab's market has matured since its commercial launch. Patent expirations and biosimilar competition will pressure revenue, with an expected downward trend over the next five years. Strategic indications expansion, partnership deals, and pipeline innovations remain critical to its sustained financial performance.

---

Key Takeaways

• Obinutuzumab generated peak sales of approximately $1.1 billion in 2019.
• Biosimilar entry beginning in 2023 is forecasted to reduce revenues significantly.
• The drug competes with rituximab biosimilars, targeted therapies, and CAR T-cell products.
• Revenue projections for 2023-2030 suggest a decline to around $0.4 billion without pipeline or indication expansion.
• Future growth depends on additional approvals and clinical use in new indications.

---

FAQs

1. How have biosimilars impacted obinutuzumab sales?
Biosimilars launched in key markets starting in 2023 have led to price reductions and market share erosion, decreasing revenue from roughly $1.1 billion in 2019 to an estimated $0.75 billion in 2023.

2. What are the primary indications for obinutuzumab?
Obinutuzumab is approved for chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL) in combination with chemotherapy.

3. Are there pipeline opportunities for obinutuzumab?
Yes, trials exploring earlier disease stages, auto-immune indications, and new combina­tions could extend its lifecycle.

4. How do target therapies compare to obinutuzumab in market share?
BTK inhibitors like ibrutinib have gained market share due to ease of use and efficacy, especially in relapsed cases, putting pressure on obinutuzumab’s long-term sales.

5. What regulatory trends could influence obinutuzumab's future?
Regulatory agencies are accelerating approval processes for biosimilars and novel therapies, which could further compress the market for branded antibodies like obinutuzumab.

---

References

[1] European Medicines Agency. (2014). Gazyva summary of product characteristics.
[2] US Food and Drug Administration. (2016). Gazyva approval letter.
[3] MarketWatch. (2022). Biologics market share analysis.
[4] EvaluatePharma. (2022). Oncology drug sales forecasts.
[5] IQVIA. (2022). Global Oncology Market Trends.